This article was reviewed by Lynn Marie Morski, MD, JD. Key Takeaways: ADHD and menopause symptoms can overlap, and one ...

An imaging study suggested prescription attention deficit hyperactivity disorder (ADHD) drugs may work differently than previously thought by affecting arousal and reward, not attention networks.

EXXUA addresses frequent causes of treatment discontinuation with first-line SSRIs and SNRIsNow commercially available through retail pharmacies and participating Aytu RxConnect pharmacies to support ...

An imaging study suggested prescription attention deficit hyperactivity disorder (ADHD) drugs may work differently than previously thought by affecting arousal and reward, not attention networks.

DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central n ...

Otsuka Pharmaceutical announced that the FDA is reviewing investigational centanafadine -- a potential first-in-class ...

From 2022 to 2024, stimulant prescriptions issued in Connecticut increased by 13.2 percent, according to data from the state.

Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor designed to address the core symptoms of ADHD in children and adults.

They said the stimulants appear to help reduce ADHD symptoms by interacting with the brain’s reward and wakefulness centers. They say the drugs also produce patterns of brain activity that are similar ...

With an expiration date still more than a year away, here's what the latest details reveal.

The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.